Loading...
•
Jun 30, 2021
Revance Q2 2021 Earnings Report
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Key Takeaways
Revance Therapeutics reported a strong second quarter with revenue totaling $18.8 million, driven by $17.0 million in RHA® Collection sales and increased fintech payment processing volume.
Q2 revenue for the RHA® Collection of dermal fillers was $17.0 million.
Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter.
Fintech payment processing volume run-rate increased to over $500 million in Q2.
FDA pre-approval inspection initiated in June, with approval of DaxibotulinumtoxinA for Injection anticipated in second half 2021.
Revance
Revance
Forward Guidance
Revance reiterates its financial guidance provided in February 2021.
Positive Outlook
- FDA approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines anticipated in 2021.
- The commercial launch of the company’s next-generation fintech platform in the fourth quarter 2021.
- Teoxane SA anticipates FDA approval for RHA® 1 for perioral (lip) lines in the second half 2021.
- Topline results from the ASPEN-OLS Phase 3 open-label, long-term safety study of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia expected in the second half 2021.
- End-of-Phase 2 meeting with the FDA anticipated in the second half 2021 for DaxibotulinumtoxinA for Injection for the treatment of adults with upper limb spasticity.